Biocon

India · 11000 Employees
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five' people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster' drugs with the potential to benefit a billion patients.

概述

国家 India
成立时间 1978
总部 20th km hosur road electronics city, bengaluru, karnataka, india
电话号码 +91 80 2808 2808
网站 http://www.biocon.com
LinkedIn http://www.linkedin.com/company/biocon
Twitter http://twitter.com/bioconlimited
Facebook http://www.facebook.com/bioconlimited
员工数 11000
行业 research,
简介 Biocon is an innovation led fully integrated biopharmaceutical company that developes affordable biosimilars, generic formulations & complex APIs

技术

Apache

Load Balancers

Bootstrap Framework

CSS and JavaScript Libraries

Cloudflare DNS

Domain Name Services

Cloudways

Hosting

Facebook Login (Connect)

Social Login

Facebook Widget

Widgets

Google Analytics

Analytics and Tracking

Google Font API

Fonts

Google Plus

Social Login

Google Tag Manager

Tag Management

Microsoft Azure

Hosting

Microsoft Azure Hosting

Hosting

Microsoft Office 365

Other

Mobile Friendly

Other

Outlook

Email Providers

SuccessFactors (SAP)

Recruitment

Ubuntu

Load Balancers

WordPress.org

CMS

YouTube

Online Video Platforms

常见问题

Biocon 在哪里?

Biocon 的总部位于 20th km hosur road electronics city, bengaluru, karnataka, india

Biocon 的电话号码是多少?

Biocon 的电话号码是 +91 80 2808 2808

Biocon 的官方网站是什么?

Biocon 的公司官方网站是 http://www.biocon.com

Biocon 是做什么的?

Biocon is an innovation led fully integrated biopharmaceutical company that developes affordable biosimilars, generic formulations & complex APIs

Biocon 的业务有哪些?

Biocon 的年收入是多少?

Biocon 的收入是 1244333000美元

Biocon 有多少员工?

Biocon 有 11000 名员工

Biocon 属于哪个行业?

Biocon 从事以下行业: research

Biocon 使用什么技术?

Biocon 使用的一些流行技术包括: Apache,Bootstrap Framework,Cloudflare DNS,Cloudways,Facebook Login (Connect),Facebook Widget,Google Analytics,Google Font API,Google Plus,Google Tag Manager,Microsoft Azure,Microsoft Azure Hosting,Microsoft Office 365,Mobile Friendly,Outlook,SuccessFactors (SAP),Ubuntu,WordPress.org,YouTube

如何联系 Biocon?

Biocon 联系信息: 电话号码:+91 80 2808 2808, 网站:http://www.biocon.com, 邮箱:ema***@***.com

Biocon 的社交媒体链接是什么?

Biocon 领英:http://www.linkedin.com/company/biocon,fackbook:http://www.facebook.com/bioconlimited,twitte:http://twitter.com/bioconlimited

Biocon 是一家上市公司吗?

是的,Biocon是一家上市公司,在nse公开挂牌上市,上市交易代码:BIOCON

Biocon 的最后一轮融资是什么时候?

暂无最近投资信息

谁投资 Biocon?

Biocon 有 0 家投资者,包括 。

外贸获客 查找关键决策人

10亿+海关交易数据,1.2亿企业数据,2亿+企业联系人数据,1000千万真实采购商。覆盖200+个国家及地区,95%外贸重点拓展市场,可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少,成就更大,销售更聪明

查找更多 B2B 联系人,丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google